

IntegraGen – Results H1 2015

Major scientific and commercial advances

- Revenue of € 2.6 million, 1% increase
- Operating income decreased by 347 K€ due to spending for further development of bioinformatics and oncology.
- Launched sequencing for microbial activity at the Institut Pasteur and strong increase in orders for clinical sequencing services
- Publication at ASCO demonstrating results from new studies confirming the role of hsa-miR-31-3p biomarker in the therapeutic treatment of patients with metastatic colon cancer
- Support of BPIfrance to the HECAM (HEpatocellular CArcinoma Multi-technological) collaborative project in liver cancer

EVRY, France (October 2, 2015) - IntegraGen (FR0010908723 - ALINT - PEA Eligible SMEs), which specializes in decoding the human genome and delivers relevant and easily interpretable analyzes for academic and private laboratories, today announces its results for the first half of 2015. The accounts were reviewed by the Board of Directors during a meeting held on October 1, 2015.

KEY INDICATORS(in thousand EUROS)	H1 2015	H1 2014	Var. %
	(6 months)	(6 months)	
Total revenue	2,624	2,592	+1%
Operating costs	(1,343)	(997)	(35%)
Net result	(872)	(746)	(17%)
	30 June 2015	31 Dec 2014	
Liquidity(in thousand EUROS)	4,050	5,237	(23%)

Courtieu Bernard, CEO, said:

"IntegraGen has confirmed its leadership in genomics and molecular diagnostics in oncology by launching several structural developments for the future growth of the company. First, we have launched the sequencing platform in microbiology at the Pasteur Institute, our second sequencing partnership with an institution which is a leader in its field following our partnership with Gustave Roussy in 2014. Second, we announced new developments in our oncology biomarker program with the replication of the role of HSA-miR-31-3p, not only in a second prospective study in colon cancer (PICCOLO), but also in two lung cancer studies, opening up prospects for our biomarker beyond only colorectal cancer. Furthermore, IntegraGen

continues to pursue the development of bioinformatics-related projects, in particular the ICE project in partnership with Gustave Roussy, INSERM, and HighTechSogeti. Finally, we are continuing our research partnership strategy with diagnostic and pharmaceutical companies constituting a new value creation step for the company."

FINANCIAL INFORMATION

▪ Income statement

Revenues for the first half 2015 amounted to 2,624 K€ compared to 2,592 K€ during the same period in 2014. This growth was limited by the amount of samples received in Q1. The pace of growth has resumed in the second quarter 2015. After taking into account operating subsidies and depreciation, amortization and provisions, revenues were 2,679 K€ versus 2,617 K€ over the first half of 2014, a 2.4% improvement.

Operating expenses amounted to 4,022 K€, an increase of 11% compared to first half 2014. This increase is due to the increase in the size of our workforce due to the recruitment of several new bioinformaticians and new cancer research collaborations.

The **operating loss** amounts to 1,343 K€ in the first half of 2014 compared to a loss of 997 K€ in the first half 2014, an increase of 26%.

The **financial result** was a loss of 65 K€. Negative exchange rate variances were recorded on purchases in dollars.

The Company recorded in the first half of 2015 an extraordinary I income amounting to 357 K€. This result consists in part of not yet amortized Coface allowances and repayable advances, as of 31 December 2014 - unamortized compensation acquired in 2015. After taking into account financial and extraordinary results and related research tax credit for research carried out during the period H1 2015, **net income** was a loss of 872 K€ over the first 6 months of the current year, against a loss of 746 K€ in the first half of 2014.

▪ Review

IntegraGen's net cash was 4,050 K€ at the end of June 2015 versus 5,237 K€ at the end of December 2014. Cash consumption remains stable and amounted to 1,187 K€ compared to 1,102 K€ during the same period in 2014.

ACTIVITY

▪ Genomic Services – strong increase in project orders

IntegraGen reports first half revenues of € 2.6 million for H1 2015, up 1% compared to the H1 2014. While the rate of growth was limited by the amount of samples received in the first quarter, the pace of growth resumed in the second quarter 2015. This seasonal effect masks the strong growth in new projects. Indeed, the order intake in the first half increased by over 25% compared to the same period of 2014, which suggests a strong performance for the second half of the year.

The development and growth of our genomic services is supported by the increased activity of the clinical genomics platform at Gustave Roussy, now operating for several hospitals, and the launch of

the microbial sequencing activity at the Institut Pasteur, which was previously announced in April. IntegraGen also recently announced in July a sequencing partnership with HEGP (European Hospital Georges Pompidou) which will also impact our business in the coming months.

While there was a slight decline in services charged to research laboratories during the first half of 2015, the company continues to contribute to advanced research efforts with many recent peer-reviewed publications in major scientific journals such as the discovery of adenovirus AAV2 in liver tumors and the identification of mutations causing retinal dystrophies.

Finally, the activity of GeCo (Genomic Consulting), an expert service in bioinformatics and biostatistics launched in the second quarter 2015, has already attracted customers and will help grow revenues throughout the year.

- **Oncology**

Further validation studies of IntegraGen's biomarker for metastatic colorectal cancer which predicts response to treatment were presented at the ASCO meeting in Chicago in May 2015. These studies demonstrated that by measuring the expression of the microRNA Has-miR-31-3p, IntegraGen is able to predict the response to the latest pharmacologic treatments in metastatic colorectal cancer. A test based on this microRNA will allow doctors to provide more timely or effective therapies to avoid unnecessary and even harmful therapies in some patients.

IntegraGen has also been selected as a partner in the HECAM project (hepatocellular carcinoma multi-technological) along with General Electric Healthcare, six other SMEs, and three academic laboratories. This research and development project aims to develop screening tools, diagnostic and treatment of hepatocellular carcinoma (HCC), the primary type of liver cancer.

- **Autism**

The company has reduced marketing efforts associated with the ARISK® Test pending the identification of a strategic marketing partner in the U.S.

ABOUT INTEGRAGEN

IntegraGen is a company that specializes in deciphering the human genome and produces relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients.

As of December 31, 2014, IntegraGen had 34 employees and had generated revenue of €6 million in 2014. Based in the Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts.

IntegraGen is listed on Alternext of Euronext Paris (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information on IntegraGen visit www.integragen.com.



CONTACTS

INTEGRAGEN

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel: +33 (0)1 60 91 09 00

NEWCAP.

Investor and Media Relations

Emmanuel HUYNH
Louis-Victor DELOUVRIER
Nicolas MERIGEAU
integragen@newcap.fr
Tel: +33 (0)1 44 71 94 94

AS OF JUNE 30, 2015

INCOME STATEMENT – INTEGRAGEN SA

<i>in K€</i>	H1 2015	H1 2014
Revenues	2,623,671	2,592,07
Other operating revenues	55,174	24,177
Total Revenues	2,678,845	2,616,584
Purchases and external expenses	(2,344,653)	(2,114,687)
Dues and taxes	(47,182)	(47,879)
Staff costs	(1,563,392)	(1,372,576)
Depreciation and amortization	(40,326)	(46,318)
Other expenses	(26,745)	(32,517)
Total operating expenses	(4,022,298)	(3,613,977)
EBIT	(1,343,453)	(997,393)
Financial products	73,838	50,567
Financial expenses	(136,881)	(41,854)
Financial result	(63,043)	(8,713)
Extraordinary income	2,256,357	1,304,003
Extraordinary expenses	(1,899,330)	(1,278,800)
Extraordinary result	357,027	25,203
Corporate income tax (R&D tax credit allowance)	177,503	217,382
Net profit	(871,966)	(746,095)

BALANCE SHEET - INTEGRAGEN SA

ASSETS

<i>in K€</i>	30/06/2015	30/06/2014
Intangible assets	3,713	5,699
Net tangible fixed assets	251,088	228,170
Net financial assets	900,156	333,667
Total assets	1,154,957	567,536
Inventory	460,399	227,133
Operating receivables	1,515,792	1,435,002
Other receivables	952,078	822,440
Treasury	4,050,188	5,849,759
Total current assets	6,978,457	8,334,334
Total assets	8,133,414	8,901,870

LIABILITIES

<i>in K€</i>	30/06/2015	30/06/2014
Capital	4,970,322	4,967,322
Share premium	35,587,392	35,592,664
Reserves and retained earnings	(36,794,517)	(35,750,912)
Results of the exercise	(871,959)	(746,096)
Shareholder's equity	2,891,238	4,062,978
Conditional advances	1,421,860	1,655,038
Provisions for risks and charges		3,557
Financial debt	281	611
Operating liabilities	1,309,192	1,350,288
Other liabilities	1,998,779	1,802,243
Total liabilities	3,308,252	3,153,142
Translation difference	512,064	27,155
Total liabilities	8,133,414	8,901,870